Alterola Biotech, Inc.

Equities

ABTI

US02152V1035

Biotechnology & Medical Research

Market Closed - OTC Markets 09:30:00 2024-04-22 am EDT 5-day change 1st Jan Change
0.0037 USD -31.48% Intraday chart for Alterola Biotech, Inc. -31.48% +2.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Alterola Biotech, Inc. Announces Executive Changes CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Alterola Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Alterola Biotech, Inc. Executive Changes CI
Alterola Biotech, Inc. Appoints Terry Rafih as A Member of Board of Directors CI
Bright Green Corporation completed the acquisition of 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl. CI
Sector Update: Health Care Stocks Rebound Slightly in Late Trade, Pare Losses MT
Sector Update: Health Care Stocks Dropping Tuesday Afternoon MT
Bright Green Corporation has signed a letter of intent to acquire a 25% stake in Alterola Biotech, Inc. (OTCPK : ABTI) from Phytotherapeutix Holdings Limited, Equipped 4 Holdings Limited and T.P.R. Global Service Srl for $4 million. CI
Alterola Biotech, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Alterola Biotech, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt CI
Alterola Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Alterola Biotech, Inc. Announces Removal of Lalit Kumar Verma as A Director CI
Alterola Biotech, Inc. completed the acquisition of the assets from C2 Wellness Corporation. CI
Alterola Biotech, Inc. signed an agreement to acquire the assets from C2 Wellness Corporation for $6.4 million. CI
Alterola Biotech, Inc. Auditor Raises 'Going Concern' Doubt CI
Alterola Biotech : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Interim CFO MT
Alterola Biotech, Inc. Announces Executive Changes CI
Alterola Biotech, Inc. Announces Executive Changes CI
Chart Alterola Biotech, Inc.
More charts
Alterola Biotech, Inc. is a pharmaceutical company. The Company is engaged in the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs); pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs; and European food approval of cannabinoid-based, cannabinoid-like, and non-cannabinoid ingredients and products. The Company has three areas of focus: development of regulated pharmaceuticals (human and animal health) and regulated food products; production of APIs and food-grade ingredients; and formulation, and drug delivery, providing bioavailability, solubility, and stability. It also focuses on developing new medicines from various sources, including botanical, traditional chemical synthesis, and biosynthetic methodologies. Its wholly owned subsidiaries include ABTI Pharma Ltd, Phytotherapeutix Ltd, and Ferven Ltd.
More about the company
  1. Stock Market
  2. Equities
  3. ABTI Stock
  4. News Alterola Biotech, Inc.
  5. Alterola Biotech : Board Replaces Outgoing CFO Larson Elsmore With Timothy Rogers as Interim CFO